Curida, Small Molecules and Biologics CDMO, Secures Equity Investment and Appoints new CEO
OSLO, NORWAY – Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm together with existing shareholders, Canica, Investinor, Klaveness Marine and Farvatn Private Equity. This investment will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry […]
Ole J. Dahlberg new CEO at Curida
Curida are happy to announce that Ole J. Dahlberg will assume the role as CEO for the company, as of January 2023. Dahlberg brings 25 years of experience from the life science industry. Over the past 15 years Dahlberg has been in executive leadership roles in Life Technologies, as Managing Director for Norway based Dynal […]
Curida acquires biologics manufacturer Diatec
Curida continues to grow in the international pharma outsourcing market. Through the acquisition of Norwegian company Diatec, Curida takes the first steps into biological production. Curida has a clear growth strategy and broadens its capabilities through the acquisition of Oslo based Diatec. This strengthens the base on which Curida aims to grow further in the […]
